Paper39677358
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
Friedberg JW and 17 others. EClinicalMedicine, 2024. Cited by 8 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial. Papers, record 39677358. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39677358
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA214890 | NCI NIH HHS | United States | R01CA214890 | PubMed and NIH | NIH RePORTER |
| U01 CA195568 | NCI NIH HHS | United States | U01CA195568 | PubMed and NIH | NIH RePORTER |
| UL1 TR002001 | NCATS NIH HHS | United States | UL1TR002001 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03078855 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma | Derived from the trial | Yes |
Source ClinicalTrials.gov
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9,060,552 | Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9060552 | PubMed |
| 2 | 33,836,479 | 25-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma. | Leuk Res | 2021 | https://conductscience.org/library/papers/33836479 | PubMed |
| 3 | 38,662,827 | Vitamin D regulates microbiome-dependent cancer immunity. | Science | 2024 | https://conductscience.org/library/papers/38662827 | PubMed |
| 4 | 25,694,350 | A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial. | Eur J Nutr | 2016 | https://conductscience.org/library/papers/25694350 | PubMed |
| 5 | 2,003,990 | Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. | Br J Cancer | 1991 | https://conductscience.org/library/papers/2003990 | PubMed |
| 6 | 23,175,624 | ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). | Ann Oncol | 2013 | https://conductscience.org/library/papers/23175624 | PubMed |
| 7 | 38,194,625 | Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38194625 | PubMed |
| 8 | 30,897,038 | AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30897038 | PubMed |
| 9 | 8,398,690 | The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8398690 | PubMed |
| 10 | 33,215,701 | Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B-cell lymphoma. | Hematol Oncol | 2021 | https://conductscience.org/library/papers/33215701 | PubMed |
| 11 | 28,841,207 | Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. | Blood Cancer J | 2017 | https://conductscience.org/library/papers/28841207 | PubMed |
| 12 | 25,135,997 | Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/25135997 | PubMed |
| 13 | 25,154,829 | Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/25154829 | PubMed |
| 14 | 25,823,738 | Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25823738 | PubMed |
| 15 | 38,701,347 | Vitamin D supplement for patients with early-stage chronic lymphocytic leukemia is associated with a longer time to first treatment. | Blood Adv | 2024 | https://conductscience.org/library/papers/38701347 | PubMed |
| 16 | 24,256,378 | Vitamin D-binding protein and vitamin D status of black Americans and white Americans. | N Engl J Med | 2013 | https://conductscience.org/library/papers/24256378 | PubMed |
| 17 | 25,113,753 | Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/25113753 | PubMed |
| 18 | 15,126,323 | Follicular lymphoma international prognostic index. | Blood | 2004 | https://conductscience.org/library/papers/15126323 | PubMed |
| 19 | 27,959,647 | Vitamin D Deficiency - Is There Really a Pandemic? | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959647 | PubMed |
| 20 | 24,794,808 | Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma. | Leuk Lymphoma | 2015 | https://conductscience.org/library/papers/24794808 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,394,759 | Vitamin D Supplementation and Treatment-Free Survival in Early-Stage CLL: A Real-World Validation Study. | EJHaem | 2026 | https://conductscience.org/library/papers/42394759 | PubMed |
| 42,163,640 | Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas. | Br J Haematol | 2026 | https://conductscience.org/library/papers/42163640 | PubMed |
| 41,884,528 | Vitamin D receptor expression in germinal centre type diffuse large B-cell lymphoma cells is associated with vitamin D insensitivity. | Endocr Oncol | 2026 | https://conductscience.org/library/papers/41884528 | PubMed |
| 41,424,936 | Current landscape of frontline and relapsed follicular lymphoma trials. | Blood Neoplasia | 2025 | https://conductscience.org/library/papers/41424936 | PubMed |
| 39,726,364 | Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia. | Eur J Haematol | 2025 | https://conductscience.org/library/papers/39726364 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1201576 | ChEMBL |
| ERGOCALCIFEROL | CHEMBL1536 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1536 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39677358
GET https://conductscience.org/api/papers/v1/39677358/references?page=2